Mylan N.V. (NASDAQ: MYL) today announced that it will host an Investor Day on April 11, 2018, in New York City. Mylan CEO Heather Bresch and the company's senior leadership team will showcase how...
Global pharmaceutical company Mylan N.V. (NASDAQ:MYL) today announced the U.S. launch of the oncology drug Mitomycin for Injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial Single Dose Vials, a...
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch two new HIV treatments, Symfi Lo™ and Cimduo™, which were approved in February by the U.S. Food and...
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the year ended December 31, 2017 and Fourth Quarter 2017 and provided 2018 guidance. Full Year 2017 Financial Highlights Total...
Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global collaboration and license agreement for the development and commercialization of a proposed...
Educational materials to help empower your customers.
What to know about our high quality generics.
Details about our brand name and generic medicines.
Resources that meet the specific needs of your institution.
Copyright © 2018 Mylan N.V. All Rights Reserved.
For U.S. Audiences Only
Please select one of our websites from the list below.
Mylan also is proud to do business in these locations.